Thyme Companies

Thyme Care, a virtual cancer navigation platform, has secured $125 million in Series E funding, boosting its valuation to over $2 billion. This capital will fuel the creation of a new parent company, Thyme Companies, aimed at addressing disparities in cancer care access, financing, and delivery. Thyme Companies will focus on critical areas like drug affordability through biosimilars and improving clinical trial enrollment. The company, now profitable and generating positive cash flow, is poised for strategic growth and innovation in tackling complex oncology challenges.